Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal desmopressin for bleeding reduction during functional endoscopic sinus surgery
IRCT20200708048051N2Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desmopressin in chronic rhinosinusitis (CRS) (3 arms), sponsored by Guilan University of Medical Sciences. Primary endpoints: Quality of surgical field, Intraoperative blood loss and 1 more. Started Feb 2021; status: completed.
02
Drugs
desmopressin
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on IRCT20200708048051N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200708048051N2.